Laura Gosa
University of California, Los Angeles
10 Papers
29 Citations
Laura Gosa is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 5, co-authored 8 publications.
Chat about Author
Papers
Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma
Wilson X. Mai,Laura Gosa,Veerle W. Daniels,Lisa Ta,Jonathan Tsang,Brian Higgins,W Blake Gilmore,Nicholas Bayley,Mitra Dehghan Harati,Jason T. Lee,William H. Yong,Harley I. Kornblum,Steven J. Bensinger,Paul S. Mischel,P. Nagesh Rao,Peter M. Clark,Timothy F. Cloughesy,Anthony Letai,David Nathanson +18 more
TL;DR: It is shown that although acute inhibition of EGFR-driven glucose metabolism induces only minimal cell death, it lowers the apoptotic threshold in a subset of patient-derived glioblastoma (GBM) cells.
Biosafety and Biohazards: Understanding Biosafety Levels and Meeting Safety Requirements of a Biobank
TL;DR: The main distinctions between BSL levels are addressed including briefly introducing hazards characteristics that classify biohazardous agents, as well as define the essentials in meeting safety requirements.
Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine.
TL;DR: The underlying biochemical and biologic basis for a variety of PET tracers and how they may be used to better optimize cancer therapy are reviewed.
21
PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation
Le Zhang,Justine Bailleul,Taha Yazal,Kevin Dong,David Sung,Amy Dao,Laura Gosa,David Nathanson,Kruttika Bhat,Sara Duhachek-Muggy,Claudia Alli,Milana Bochkur Dratver,Frank Pajonk,Erina Vlashi +13 more
TL;DR: The results show that activators of PK-M2 can deplete breast cancer stem cells in vitro, which supports the idea of combining PK- M2 activators with radiation to enhance the effect of radiotherapy in resistant cancers, such as TNBC.
18
Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial.
Jeremie Calais,Jeannine Gartmann,Wesley R Armstrong,Pan Thin,Kathleen Nguyen,Vincent Lok,Laura Gosa,Roger Slavik,Magnus Dahlbom,Ken Herrmann,Matthias Eiber,Wolfgang P. Fendler,Johannes Czernin +12 more
TL;DR: This was an open-label randomized prospective bi-centric single-arm phase II clinical trial of 177Lu-PSMA-617 molecular radiotherapy in patients with progressive metastatic castrate...
6